{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-017398","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.989998+00:00","generated_at":"2026-06-15T01:47:36.988897+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sanara MedTech Q1 revenue $15.5M, up 99% YoY; net loss narrows to $1.2M","bullets":["Net revenues $15.5M (99% YoY increase); net loss $1.2M vs $3.2M prior year.","Gross margin 86% vs 90% prior year due to lower margins on Scendia products.","SG&A $13.0M (up $3.6M) driven by higher sales commissions and sales force expansion.","Scendia sales flat at $3.0M; ALLOCYTE supply issues persist, expected resolution H2 2023.","Received 510(k) clearance for BIASURGE Advanced Surgical Solution; preparing launch late 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-017398","json":"https://secwatch.observer/filing/0001493152-23-017398.json","markdown":"https://secwatch.observer/filing/0001493152-23-017398.md","text":"https://secwatch.observer/filing/0001493152-23-017398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315223017398/0001493152-23-017398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315223017398/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:47:36.988897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7242f118579a532f7ceff041b37ea5fdad5c8ed6","claim":"Sanara MedTech Inc. reported the quarter ended March 31, 2023 results: revenue $15.5 million, net income net loss of $1.2 million.","evidence_excerpt":"clearance for BIASURGETM. First Quarter 2023 Consolidated Financial Results (Unaudited) ● Net Revenues. For the three months ended March 31, 2023, we generated net revenues of $15.5 million compared to net revenues of $7.8 million for the three months ended March 31, 2022, a 99% increase from the prior year period. Our net revenues for the three months ended March","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/714256/000149315223017398/0001493152-23-017398-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$15.5 million"},{"label":"Net income","value":"net loss of $1.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}